Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Paul M. Barr et al.|New England Journal of Medicine|2014Cited by 1.6k
Non-coding recurrent mutations in chronic lymphocytic leukaemiaXosé S. Puente, María José Terol, Sı́lvia Beà et al.|Nature|2015Cited by 851
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W. Flinn, Stephan Stilgenbauer, Peter Hillmen et al.|Blood|2018Cited by 341
Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemiaGabriel Bretones, Carlos López-Otı́n, M. Alvarez et al.|Blood|2018Cited by 61
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S. Davids, Ulrich Jäger, Bryone J. Kuss et al.|Clinical Cancer Research|2020Cited by 43